After 48 weeks of blinded treatment, participants will continue to take blinded study drug for 12 weeks and return for an Unblinding Visit at Week 60. Participants who are virologically suppressed at Week 48 during the Double-Blinded Treatment Phase will have the option to enter the OLE Phase.